FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1994499261> ?p ?o ?g. }

• W1994499261 endingPage "17" @default.
• W1994499261 startingPage "9" @default.
• W1994499261 abstract "Despite more than a decade of research in the field of endocrine active compounds targeting the androgen receptor (AR), and although suitable cell lines can be obtained, no validated human stably transfected androgen sensitive transactivation assay is available. Bayer Schering Pharma (BSP) and the Flemish Institute for Technological Research (VITO), partners within the EU-sponsored 6th framework project ReProTect, made first steps towards such a validation. A standard operation protocol (SOP) developed at BSP based on the androgen sensitive PALM cell line was transferred to VITO and its performance and transferability were thoroughly studied. The investigation followed a generic protocol prepared for all reporter gene assays evaluated within ReProTect, and in both laboratories at least three independent experiments were performed. The highest concentration to be tested was limited to 10 μM, if needed. A few compounds, 17α-methyltestosterone (17α-MT), vinclozolin and linuron, were studied using a real world scenario, i.e., assuming that their interaction with the AR was not known: A prescreening for agonism and true, competitive antagonism was used to select conditions such as the appropriate mode of action, and the working range excluding cytotoxicity for the final screening. All other compounds were tested according to the generic protocol: Compounds screened for agonism were the reference androgen 17α-methyldihydrotestosterone (MDHT), levonorgestrel, norethynodrel, progesterone, o,p′-DDT, and dibutylphthalate (DBP), while compounds screened for antagonism were the reference anti-androgen flutamide, prochloraz, o,p′-DDT, progesterone, norethynodrel, and DBP. Cytotoxicity was assessed in parallel as lactate dehydrogenase release. The prescreen classified 17α-MT as androgenic, vinclozolin and linuron as anti-androgenic and compounds were tested accordingly. In the absence of cytotoxicity, appropriate androgenic properties of reference and test compounds were detected by both laboratories, o,p′-DDT and DBP had no androgenic activity. Across the two laboratories EC50-values for MDHT, 17α-MT, and levonorgestrel varied by not more than a factor of 3.4, for norethynodrel by a factor of 9.7. Progesterone effects could not fully be evaluated, as frequently concentration response curves were incomplete. In the absence of cytotoxicity anti-androgenic properties of reference and test compounds were also detected in both laboratories. DBP, the putative negative reference compound, was inactive, norethynodrel rather showed agonistic properties. Progesterone was an antagonist at low concentrations, but agonistic properties were observed in one laboratory at high concentrations. Since the highest test concentration was limited to 10 μM, for some compounds no complete concentration response curves were obtained and estimation of EC50-values was less robust. Our data demonstrated that the SOP was transferable, and that the assay was able to rank compounds with strong, weak, and without affinity for the AR and to discriminate agonists and antagonists. The sensitivity of the assay could be improved further, if the limit of solubility or beginning cytotoxicity was chosen as the highest test concentration. The assay avoids the use of tissues from laboratory animals, and thus contributes to the 3R concept. Furthermore, it could be adjusted to an intermediate/high throughput format. On the whole, this PALM assay is a promising candidate for further validation." @default.
• W1994499261 created "2016-06-24" @default.
• W1994499261 creator A5004617313 @default.
• W1994499261 creator A5013258216 @default.
• W1994499261 creator A5035468667 @default.
• W1994499261 creator A5041996792 @default.
• W1994499261 creator A5042424226 @default.
• W1994499261 creator A5053915330 @default.
• W1994499261 date "2010-08-01" @default.
• W1994499261 modified "2023-09-24" @default.
• W1994499261 title "Screening for (anti)androgenic properties using a standard operation protocol based on the human stably transfected androgen sensitive PALM cell line. First steps towards validation" @default.
• W1994499261 cites W1251710288 @default.
• W1994499261 cites W1984129493 @default.
• W1994499261 cites W2001469968 @default.
• W1994499261 cites W2009040345 @default.
• W1994499261 cites W2017900385 @default.
• W1994499261 cites W2027299212 @default.
• W1994499261 cites W2060223401 @default.
• W1994499261 cites W2070789722 @default.
• W1994499261 cites W2083040570 @default.
• W1994499261 cites W2084279961 @default.
• W1994499261 cites W2120798598 @default.
• W1994499261 cites W2136238203 @default.
• W1994499261 cites W2139685584 @default.
• W1994499261 cites W2145090359 @default.
• W1994499261 cites W2152344953 @default.
• W1994499261 cites W2158537274 @default.
• W1994499261 cites W2161035857 @default.
• W1994499261 cites W2161286968 @default.
• W1994499261 doi "https://doi.org/10.1016/j.reprotox.2009.10.002" @default.
• W1994499261 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19836445" @default.
• W1994499261 hasPublicationYear "2010" @default.
• W1994499261 type Work @default.
• W1994499261 sameAs 1994499261 @default.
• W1994499261 citedByCount "17" @default.
• W1994499261 countsByYear W19944992612012 @default.
• W1994499261 countsByYear W19944992612013 @default.
• W1994499261 countsByYear W19944992612014 @default.
• W1994499261 countsByYear W19944992612015 @default.
• W1994499261 countsByYear W19944992612016 @default.
• W1994499261 countsByYear W19944992612017 @default.
• W1994499261 countsByYear W19944992612018 @default.
• W1994499261 countsByYear W19944992612020 @default.
• W1994499261 crossrefType "journal-article" @default.
• W1994499261 hasAuthorship W1994499261A5004617313 @default.
• W1994499261 hasAuthorship W1994499261A5013258216 @default.
• W1994499261 hasAuthorship W1994499261A5035468667 @default.
• W1994499261 hasAuthorship W1994499261A5041996792 @default.
• W1994499261 hasAuthorship W1994499261A5042424226 @default.
• W1994499261 hasAuthorship W1994499261A5053915330 @default.
• W1994499261 hasConcept C104317684 @default.
• W1994499261 hasConcept C121608353 @default.
• W1994499261 hasConcept C126322002 @default.
• W1994499261 hasConcept C1292079 @default.
• W1994499261 hasConcept C134018914 @default.
• W1994499261 hasConcept C185592680 @default.
• W1994499261 hasConcept C2777911890 @default.
• W1994499261 hasConcept C2778586440 @default.
• W1994499261 hasConcept C2780192828 @default.
• W1994499261 hasConcept C2780482068 @default.
• W1994499261 hasConcept C2910322876 @default.
• W1994499261 hasConcept C530470458 @default.
• W1994499261 hasConcept C55493867 @default.
• W1994499261 hasConcept C61367390 @default.
• W1994499261 hasConcept C71315377 @default.
• W1994499261 hasConcept C71924100 @default.
• W1994499261 hasConcept C84606932 @default.
• W1994499261 hasConcept C86339819 @default.
• W1994499261 hasConcept C86803240 @default.
• W1994499261 hasConcept C98274493 @default.
• W1994499261 hasConceptScore W1994499261C104317684 @default.
• W1994499261 hasConceptScore W1994499261C121608353 @default.
• W1994499261 hasConceptScore W1994499261C126322002 @default.
• W1994499261 hasConceptScore W1994499261C1292079 @default.
• W1994499261 hasConceptScore W1994499261C134018914 @default.
• W1994499261 hasConceptScore W1994499261C185592680 @default.
• W1994499261 hasConceptScore W1994499261C2777911890 @default.
• W1994499261 hasConceptScore W1994499261C2778586440 @default.
• W1994499261 hasConceptScore W1994499261C2780192828 @default.
• W1994499261 hasConceptScore W1994499261C2780482068 @default.
• W1994499261 hasConceptScore W1994499261C2910322876 @default.
• W1994499261 hasConceptScore W1994499261C530470458 @default.
• W1994499261 hasConceptScore W1994499261C55493867 @default.
• W1994499261 hasConceptScore W1994499261C61367390 @default.
• W1994499261 hasConceptScore W1994499261C71315377 @default.
• W1994499261 hasConceptScore W1994499261C71924100 @default.
• W1994499261 hasConceptScore W1994499261C84606932 @default.
• W1994499261 hasConceptScore W1994499261C86339819 @default.
• W1994499261 hasConceptScore W1994499261C86803240 @default.
• W1994499261 hasConceptScore W1994499261C98274493 @default.
• W1994499261 hasIssue "1" @default.
• W1994499261 hasLocation W19944992611 @default.
• W1994499261 hasLocation W19944992612 @default.
• W1994499261 hasOpenAccess W1994499261 @default.
• W1994499261 hasPrimaryLocation W19944992611 @default.
• W1994499261 hasRelatedWork W1572019026 @default.
• W1994499261 hasRelatedWork W2031423015 @default.
• W1994499261 hasRelatedWork W2042646980 @default.

• next